Laboratory operator Quest Diagnostics beat Wall Street estimates for first-quarter profit on Tuesday, helped by robust demand for its diagnostic tests.

Evergreen Capital Management boosted its Regeneron stake by 362.9%, snatching up 3,030 more shares and flexing some serious ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $831.43, with a high estimate of $1013.00 and a low estimate of $547.00. Highlighting a 8.86% ...

Analysts at Leerink agreed with Sanofi that, despite falling short of statistical significance in the Phase II TIDE-Asthma trial, amlitelimab warrants further development in this indication.

That wound up well above expectations, Leerink Partners analyst Whit Mayo said in a research note. BTIG analyst David Larsen said separately that the final increase more than doubled what was ...

which also includes deep finance teams within each individual business,” analysts from Leerink Partners wrote in a note to clients. CVS also named Amy Compton-Phillips the company’s new ...

On Tuesday, Leerink Partners maintained its Outperform rating on CVS Health (NYSE:CVS) shares with a steady price target of $75.00. According to InvestingPro data, CVS Health, currently trading at ...

Leerink Partnrs analyst M. Cherny now expects that the medical research company will earn $2.58 per share for the quarter, down from their prior estimate of $2.59. Leerink Partnrs currently has a ...

On the bright side, Leerink Partners upgraded Regeneron to a “strong-buy,” proving at least one analyst still believes in scientific miracles and stock rebounds. Despite the lukewarm analyst sentiment ...

Regeneron Pharmaceuticals saw its share price decline by 10% over the past week. The recent approval of Dupixent for COPD in Japan was expected to bolster investor confidence, yet the broader ...